Nutriband (NASDAQ:NTRB - Get Free Report) posted its earnings results on Monday. The company reported ($0.18) earnings per share for the quarter, missing analysts' consensus estimates of ($0.12) by ($0.06), Zacks reports. Nutriband had a negative return on equity of 54.49% and a negative net margin of 338.51%.
Nutriband Trading Up 9.8 %
NASDAQ:NTRB traded up $0.52 during midday trading on Monday, hitting $5.84. 53,832 shares of the company traded hands, compared to its average volume of 74,962. The firm has a market capitalization of $64.86 million, a P/E ratio of -8.23 and a beta of 1.19. The firm's fifty day moving average is $6.08 and its 200-day moving average is $5.74. Nutriband has a 12-month low of $3.30 and a 12-month high of $11.78. The company has a current ratio of 4.96, a quick ratio of 4.83 and a debt-to-equity ratio of 0.01.
Analyst Ratings Changes
Separately, Noble Financial assumed coverage on Nutriband in a research report on Wednesday, January 22nd. They issued an "outperform" rating and a $13.00 price target for the company.
Check Out Our Latest Analysis on NTRB
Nutriband Company Profile
(
Get Free Report)
Nutriband Inc develops a portfolio of transdermal pharmaceutical products. Its lead product in development is AVERSA fentanyl, an abuse deterrent fentanyl transdermal system that provides clinicians and patients with an extended-release transdermal fentanyl product for use in managing chronic pain requiring around the clock opioid therapy.
Featured Articles
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Nutriband, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Nutriband wasn't on the list.
While Nutriband currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Learn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
